{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-072058","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2024-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.164890+00:00","generated_at":"2026-06-01T04:08:59.810152+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Aerovate Phase 2b trial of AV-101 fails primary endpoint; halts Phase 3 and extension","bullets":["AV-101 did not meet primary endpoint of PVR improvement at any dose (10, 35, 70 mg BID); p-values all >0.36.","Secondary endpoint 6MWD also showed no meaningful improvement; LS mean differences ranging -11.7 to +1.3 meters.","Company halting enrollment and shutting down Phase 3 IMPAHCT and long-term extension study, per advisory committee.","Cash position ~$100M as of June 15, 2024; CEO calls results unexpected and disappointing.","Full Phase 2b data release timing to be determined; no new clinical path announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-072058","json":"https://secwatch.observer/filing/0001104659-24-072058.json","markdown":"https://secwatch.observer/filing/0001104659-24-072058.md","text":"https://secwatch.observer/filing/0001104659-24-072058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000110465924072058/0001104659-24-072058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000110465924072058/tm2417394d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:08:59.810152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}